New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:58 EDTLGND, GSKLigand says partner GSK submits application for Promacta
Ligand Pharmaceuticals (LGND) said its partner GlaxoSmithKline (GSK) announced today the submission of a supplemental New Drug Application to the FDA for Promacta for the treatment of cytopenias in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
News For LGND;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 3, 2015
18:11 EDTGSKSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
07:43 EDTGSKExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
16:59 EDTGSKGlaxoSmithKline, Theravance announce FDA approval of Breo Ellipta
Subscribe for More Information
15:20 EDTGSKGlaxo says FDA issued CRL on use of Breo Ellipta in patients aged 12-17
Subscribe for More Information
15:17 EDTGSKGlaxoSmithKline says FDA approves BREO ELLIPTA for adults with asthma
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
07:21 EDTGSKFDA PDUFA Date for Theravance BREO ELLIPTA is April 30, 2015
April 27, 2015
10:04 EDTGSKHigh option volume stocks
Subscribe for More Information
08:46 EDTGSKAgenus data positive, says JMP Securities
Subscribe for More Information
08:41 EDTGSKTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTGSKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
April 23, 2015
16:14 EDTLGNDLigand names Melanie Herman Interim CFO
Subscribe for More Information
April 22, 2015
12:01 EDTLGNDLigand earns milestone payment from Sage Therapeutics for SAGE-547
Ligand (LGND) announced that it has earned a $500,000 milestone payment from SAGE Therapeutics (SAGE) relating to the treatment of the first patient in SAGE’s Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus and to evaluate the safety of SAGE-547 in patients with SRSE. SAGE has reported that the results from this clinical trial, along with results from SAGE's planned Phase 3 placebo-controlled clinical trial - called the STATUS Trial – and other clinical data obtained from the SAGE-547 development program are intended to form the basis of a New Drug Application submission.
April 21, 2015
09:16 EDTLGNDTG Therapeutics data positive, says Roth Capital
Subscribe for More Information
April 20, 2015
07:41 EDTLGNDLigand partner TG Therapeutics presents pre-clinical data on IRAK4 compounds
Subscribe for More Information
07:20 EDTGSKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use